NDC 0186-0777
BRILINTA
Ticagrelor
BRILINTA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Ticagrelor.
| Product ID | 0186-0777_0127d327-2b47-41ce-b603-4ddc0fc7cca8 |
| NDC | 0186-0777 |
| Product Type | Human Prescription Drug |
| Proprietary Name | BRILINTA |
| Generic Name | Ticagrelor |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2011-08-05 |
| Marketing Category | NDA / NDA |
| Application Number | NDA022433 |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Substance Name | TICAGRELOR |
| Active Ingredient Strength | 90 mg/1 |
| Pharm Classes | P2Y12 Platelet Inhibitor [EPC],Phenylalanine Hydroxylase Activators [MoA],Decreased Platelet Aggregation [PE],P2Y12 Receptor Antagonists [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A5 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
Packaging
NDC 0186-0777-08
8 TABLET in 1 BOTTLE (0186-0777-08)
| Marketing Start Date | 2011-08-05 |
| NDC Exclude Flag | N |
| Sample Package? | Y |
NDC SPL Data Element Entries
NDC 0186-0777-60 [00186077760]
BRILINTA TABLET
| Marketing Category | NDA |
| Application Number | NDA022433 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2011-08-05 |
NDC 0186-0777-18 [00186077718]
BRILINTA TABLET
| Marketing Category | NDA |
| Application Number | NDA022433 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2011-08-05 |
| Marketing End Date | 2011-08-05 |
NDC 0186-0777-08 [00186077708]
BRILINTA TABLET
| Marketing Category | NDA |
| Application Number | NDA022433 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2011-08-05 |
NDC 0186-0777-39 [00186077739]
BRILINTA TABLET
| Marketing Category | NDA |
| Application Number | NDA022433 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2011-08-05 |
NDC 0186-0777-28 [00186077728]
BRILINTA TABLET
| Marketing Category | NDA |
| Application Number | NDA022433 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2011-08-05 |
| Marketing End Date | 2017-04-28 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| TICAGRELOR | 90 mg/1 |
Pharmacological Class
- P2Y12 Platelet Inhibitor [EPC]
- Phenylalanine Hydroxylase Activators [MoA]
- Decreased Platelet Aggregation [PE]
- P2Y12 Receptor Antagonists [MoA]
- Cytochrome P450 3A4 Inhibitors [MoA]
- Cytochrome P450 3A5 Inhibitors [MoA]
- P-Glycoprotein Inhibitors [MoA]
NDC Crossover Matching brand name "BRILINTA" or generic name "Ticagrelor"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0186-0776 | BRILINTA | Ticagrelor |
| 0186-0777 | BRILINTA | Ticagrelor |
| 55154-9618 | BRILINTA | Ticagrelor |
| 69238-1134 | ticagrelor | ticagrelor |
Trademark Results [BRILINTA]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 BRILINTA 78457162 3040606 Live/Registered |
AstraZeneca AB 2004-07-27 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.